المرجو من الزائرين للصفحة دعمنا بالاعجاب و التعليق و المشاركة Les pedimos amablemente a los visitantes de esta página que nos apoyen dándole "me gusta", comentando y compartiendo. We kindly ask visitors to this page to support us by liking, commenting, and sharing. Мы просим посетителей этой страницы поддержать нас, поставив лайк, оставив комментарий и поделившись информацией. 이 페이지를 방문하신 분들께서는 좋아요, 댓글, 공유를 통해 저희를 지원해 주시기 바랍니다. 懇請各位訪客透過按讚、留言和分享來支持我們。 このページの訪問者の皆様には、いいね、コメント、シェアなどでサポートしていただきますようお願いいたします。 हम इस पेज पर आने वाले आगंतुकों से अनुरोध करते हैं कि वे इसे लाइक, कमेंट और शेयर करके हमारा समर्थन करें। Nous demandons gentiment aux visiteurs de cette page de nous soutenir en aimant, commentant et partageant.

Translate

Contact Form

Name

Email *

Message *

Search This Blog

Introduction: Venous thromboembolism (VTE) is a frequent and serious complication in cancer patients. Nonetheless,

 


Abstract

Introduction: Venous thromboembolism (VTE) is a frequent and serious complication in cancer patients. Nonetheless, patients with hematological cancers receive less attention as compared with their solid tumor counterparts regarding this potentially fatal complication.Areas covered: Risk factors that are associated with the development of VTE in hematological cancers are discussed, based on a PubMed literature search. Since different hematological malignancies carry different risk of VTE, risk assessment in individual types of hematological cancers, including acute leukemias, lymphomas, myeloma and myeloproliferative neoplasms, are examined separately. Clinical relevance of VTE assessment and current guidelines on thromboprophylaxis in patients with hematological malignancies are also briefly reviewed.Expert opinion: When assessing VTE risk in patients with hematological cancers, in addition to the non-cancer specific risk factors, individual cancer-type specific and the therapy-related factors must be taken into consideration. Primary thromboprophylaxis should be considered in high risk patients.

PMID: 32249620 [PubMed - as supplied by publisher]

13:27

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

13:27

In reply to this message

pubmed: ctoall&ca or conall

Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative.


Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative.


Oncologist. 2020 Apr 06;:


Authors: Reding KW, Aragaki AK, Cheng RK, Barac A, Wassertheil-Smoller S, Chubak J, Limacher MC, Hundley WG, D'Agostino R, Vitolins MZ, Brasky TM, Habel LA, Chow EJ, Jackson RD, Chen C, Morgenroth A, Barrington WE, Banegas M, Barnhart M, Chlebowski RT


No comments:

Post a Comment

اكتب تعليق حول الموضوع